New hope for blood cancer patients: Two-Drug combo enters final testing
NCT ID NCT07357727
Summary
This study is testing whether adding a new drug called pelabresib to the standard treatment (ruxolitinib) works better for adults with myelofibrosis, a serious bone marrow cancer. It will enroll 460 patients who have not yet tried JAK inhibitor drugs. The main goals are to see if the combination shrinks enlarged spleens more effectively and reduces symptoms like fatigue and pain compared to the standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS (PMF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.